By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ernst & Young LLP 

Global Biotechnology Center
200 Clarendon Street
Boston  Massachusetts  02116  U.S.A.
Phone: 617-859-6400 Fax: 617-266-5843


Ernst & Young pioneered professional services in support of biotechnology and is recognized as the leader in serving the industry. Since the industry's inception, Ernst & Young has consistently met the changing business needs of biotech companies, helping them address a range of critical business issues including:

- Product development and commercialization
- Strategic asset management
- Regulatory strategy and compliance
- Financial planning
- Information systems and technology
- Business performance improvement
- International business development
- Business planning
- New venture development
- Corporate development
- Strategic partnering
- International tax strategy
- Transactions
- Corporate finance
- Worldwide accounting, auditing, and tax

Ernst and Young biotechnology service teams are part of an extensive global network of professionals with industry-specific backgrounds. Our service philosophy is based on the effective integration of the people, processes, and technology for enterprise-wide improvement.

Ernst & Young is committed to supporting companies within each phase of the life sciences industry life cycle. Whether yours is a mature company or a visionary start-up, we can help. Our long-standing commitment to life sciences companies, coupled with our technical services capabilities, makes Ernst & Young the firm of choice for the biotechnology industry.

Key Statistics

Ownership: Private

Web Site: Ernst & Young LLP


Company News
Antibe Therapeutics (ATE.V) Release: Biotech Announces Change Of Auditor To Ernst & Young LLP 1/19/2017 8:25:42 AM
Ernst & Young LLP Names BioMarin (BMRN) CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year 2015 National Award Winner in Life Sciences 11/16/2015 10:54:48 AM
New White Paper From BIO, National Organization for Rare Disorders, And Ernst & Young LLP Finds Orphan Drug Tax Credit Is Crucial To Rare Disease R&D 6/17/2015 9:52:41 AM
Inovio Pharmaceuticals (INO) CEO Named "Entrepreneur Of The Year" By Ernst & Young LLP 6/12/2015 7:46:21 AM
PDL BioPharma, Inc. (PDLI) Issues Statement On Resignation Of Ernst & Young LLP As Corporate Auditors 9/18/2014 8:15:57 AM
Advanced Cell Technology Announces Paul K. Wotton Ph.D. Recognized As Ernst & Young LLP 2014 Entrepreneur Of The Year™ For New Jersey Region 7/1/2014 10:33:53 AM
Atherotech Diagnostics Lab President And CEO Wins Ernst & Young LLP Entrepreneur Of The Year Award 6/30/2014 10:02:47 AM
Intrexon (XON) Appoints Former Ernst & Young LLP CEO James S. Turley To Board Of Directors 4/17/2014 6:23:12 AM
NPS Pharmaceuticals, Inc. (NPSP)’ President And CEO Dr. Francois Nader Receives Ernst & Young LLP National Entrepreneur Of The Year® 2013 Award In The Life Sciences Category 11/18/2013 10:09:30 AM
Ernst & Young LLP Announces Labcyte Inc. CEO and President Mark Fischer-Colbrie and Co-Founder Rich Ellson as the Entrepreneur Of The Year® 2013 Award Winner in Northern California 7/24/2013 9:53:13 AM